ClinicalTrials.Veeva

Menu

Blood Bioavailability of Two Different Doses of a β-alanine Supplement (BIo-β) (Bio-β)

U

Universidad Católica San Antonio de Murcia

Status

Completed

Conditions

Bioavailability

Treatments

Dietary Supplement: Low dose
Dietary Supplement: High dose

Study type

Interventional

Funder types

Other

Identifiers

NCT06214338
UCAMCFE-00035

Details and patient eligibility

About

The purpose of this study is to To study the blood bioavailability of a sustained-release β-alanine granulated supplement of two different doses (10 g and 20 g).

Full description

Subjects will consume 10 g of β-alanine one day by 4 ingestions of 2.5 g separated by 1 hour and 15 min. While on another day 20 g of β-alanine by 4 ingestions of 5 g separated by 1 hour and 15 minutes, with a washout period of 15 days between the two doses. Subsequently, the amino acid levels in blood will be analyzed after the product intake and during a period of 8 hours.

Each day of visit the paresthesias (moment of appearance, intensity and sensations) will be studied at different times.

Enrollment

12 patients

Sex

Male

Ages

18 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Men between 18 and 60 years old.
  • Cyclists with more than two years of cycling experience.
  • Bicycle training at least twice a week.

Exclusion criteria

  • Suffer a lasting injury that prevents you from training in the month prior to surgery.
  • Subjects with a chronic illness.
  • Having consumed in the three months prior to the start of the study any β-alanine supplement.
  • Making changes in diet or exercise during the study.
  • Inability to understand the informed consent form.
  • Consumption of other supplements that could alter the results of the study.

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Triple Blind

12 participants in 2 patient groups

Low Dose
Experimental group
Description:
10 mg of β-alanine
Treatment:
Dietary Supplement: Low dose
High Dose
Experimental group
Description:
20 mg of β-alanine
Treatment:
Dietary Supplement: High dose

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems